▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 29, 2024

Bio

PCL hopes to raise W20b via IPO

  • PUBLISHED :December 12, 2016 - 17:26
  • UPDATED :December 12, 2016 - 17:27
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print

[THE INVESTOR] South Korea’s in vitro diagnostics company PCL said Dec. 12 it will seek to boost its market share ahead of its planned initial public offering next week.

PLC seeks to raise up to 21.6 billion won (US$18.47 million) by floating its shares on the tech-heavy KOSDAQ on Dec. 28. The IPO proceeds will be used for research and development as well as facility expansion. 


PCL CEO Kim So-youn



“Development opportunities of in vitro diagnostics are infinite by utilizing our original technology and multi-diagnostics platform,” said the firm’s CEO Kim So-youn in a press conference held in Seoul.

According to Kim, PCL has begun to sell its multiplex immunodiagnostic screening kit called Hi3-1 this year, designed for the blood donor diagnostic screening, to France, Brazil and Germany after receiving European Conformity Marking, the official stamp of approval to launch products in the market.

“Demand for our product is expected to increase for emergency use and infectious diseases,” she said.

With such market expansion, the company aims to log 28 billion won in sale by 2019.

The biotech firm will gauge demand for the share sale on Dec. 14-15 and set its IPO price.

It has set an indicative price range of 11,300 won to 14,400 won.

Korea Investment & Securities is the lead underwriter for the proposed deal.

By Park Han-na (hnpark@heraldcorp.com)

EDITOR'S PICKS